Compare AORT & TNDM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AORT | TNDM |
|---|---|---|
| Founded | 1984 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.0B |
| IPO Year | 1996 | 2013 |
| Metric | AORT | TNDM |
|---|---|---|
| Price | $24.04 | $15.17 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 19 |
| Target Price | ★ $49.40 | $28.00 |
| AVG Volume (30 Days) | 763.4K | ★ 1.8M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 165.62 | N/A |
| EPS | ★ 0.03 | N/A |
| Revenue | $298,836,000.00 | ★ $1,014,736,000.00 |
| Revenue This Year | $14.20 | $8.11 |
| Revenue Next Year | $11.20 | $11.85 |
| P/E Ratio | $773.67 | ★ N/A |
| Revenue Growth | ★ 18.01 | 7.93 |
| 52 Week Low | $19.16 | $10.00 |
| 52 Week High | $48.25 | $29.65 |
| Indicator | AORT | TNDM |
|---|---|---|
| Relative Strength Index (RSI) | 54.70 | 44.90 |
| Support Level | $19.49 | $14.80 |
| Resistance Level | $25.04 | $16.00 |
| Average True Range (ATR) | 1.12 | 0.87 |
| MACD | 0.25 | 0.06 |
| Stochastic Oscillator | 69.03 | 31.09 |
Artivion Inc offers cardiac and vascular surgeons a suite of aortic-centric solutions. The company's products include Aortic Heart Valve, Mitral Heart Valve, Aortic Allograft, Pulmonary Human Heart Valve, Pulmonary Patch, and Surgical Adhesive among others. The company's has two reportable segments: Medical Devices and Preservation Services. The Medical Devices segment includes revenues from sales of aortic stent grafts, surgical sealants, On-X products, and other product revenues. The Preservation Services segment includes services revenues from the preservation of cardiac and vascular implantable human tissues. Company operates in North America, EMEA. LATAM, APAC. Maximum revenue is from North America.
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on Tobi (a tubeless version of Mobi), and the Sigi tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 2 to 3 days.